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ABSTRACT

Salisbury Jr., Richard L. Ph.D., Environmental Sciences Ph.D. program, Wright
State University, 2014. TCDD represses 3’IghRR activation through an AhRdependent shift in the NF-κB/Rel protein complexes binding to κB motifs within
the hs1,2 and hs4 enhancers

Transcriptional regulation of the murine immunoglobulin heavy chain gene
involves several regulatory elements including the 3′Igh regulatory region
(3′IghRR) composed of at least four enhancers (hs3A; hs1,2; hs3B; hs4).
Enhancers hs1,2 and hs4 contain binding sites for several transcription factors
including NF-κB/Rel proteins and the AhR. Interestingly, 2,3,7,8tetrachlorodibenzo-p-dioxin (TCDD) profoundly inhibits 3′IghRR and hs1,2
activation induced by the B-cell activator lipopolysaccharide (LPS), but enhances
the activation of the hs4. Within the hs4, the AhR binding site overlaps an NFκB/Rel binding site suggesting that both the AhR and the NF-κB together may
modulate of the 3’IghRR. The objective of the current study was to evaluate the
role of NF-κB/Rel and the AhR following LPS stimulation and TCDD treatment on
3′IghRR, hs1,2, and hs4. In our studies we utilized the CH12.LX B cell line; the
CH12.IκBαAA cell line, which expresses an inducible IκBα super repressor
(IκBαAA); the CH12.γ2b-3′IghRR cell line that stably expresses a γ2b-3′IghRRregulated gamma2b transgene reporter; and splenocytes derived from B6C3F1
iii

mice. The stimulation of the CH12.γ2b-3′IghRR cell line with Toll-like receptor
(TLR) agonists LPS, Resiquimod (R848), or Cytosine-phosphate-Guanine (CpG)oligodeoxynucleotides combined with a co-treatment of TCDD significantly
inhibited the TLR-induced activation of the 3’IghRR. Utilizing transiently
expressed luciferase reporters, we found induction of IκBαAA expression
partially attenuated LPS-induced activation of the 3’IghRR and hs4, partially
reversed the effects of a TCDD and LPS co-treatment on the activity of the
3’IghRR and hs4, and the addition of an AhR antagonist, CH223191, markedly
reversed the LPS and TCDD induced inhibition of the 3’IghRR and inhibited the
synergistic activation of the hs4. Chromatin immunoprecipitation analysis of
CH12.LX and murine splenocytes demonstrated a LPS and a LPS co-treatment
with TCDD-dependent increase in RelA and AhR binding, and a significant
decrease in RelB binding to the hs4 and hs1,2. These results suggest that a shift
in binding of the NF-κB/Rel proteins, perhaps through an interaction with the AhR
are partially responsible for 3′IghRR modulation by LPS and TCDD. These
results suggest that interactions between the AhR and NF-κB within the 3’IghRR
mediate the inhibitory effects of TCDD on immunoglobulin (Ig) expression and
therefore antibody levels.
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CHAPTER 1. BACKGROUND
Summary
The proposed studies focus on understanding how dioxin, specifically
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), impacts host resistance to infections
mediated by B cells. B cells are the effector cells of the humoral immune
response that produce and secrete immunoglobulins (Ig). TCDD has been shown
to markedly inhibit Ig expression and secretion in vivo and in several in vitro
models which appears to be dependent on activation of the aryl hydrocarbon
receptor (AhR) signaling pathway (Holsapple, Dooley et al. 1986; Dooley and
Holsapple 1988; North, Crawford et al. 2009). Binding of dioxin and dioxin-like
compounds to the cytosolic AhR represents the first step in a series of events
that results in nuclear translocation of the AhR which is a ligand-activated
transcription factor. Upon translocation of the AhR, the AhR binds to dioxin
responsive elements (DRE) in dioxin sensitive genes and elicits transcription
(Pollenz 1996; Swanson 2002).
B-cell differentiation into immunoglobulin secreting cells is dependent on
cellular activation. Cellular activation can be initiated by various extracellular
stimuli leading to an intracellular signaling cascade. Of the many potential
activation pathways, activation of the nuclear factor-κB (NF-κB)/Rel proteins play
a significant role in cellular activation. NF-κB/Rel proteins (RelA, RelB, c-Rel,
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p50, p52) are transcription factors that bind as dimers to κB sites within
the DNA, and based upon the composition of the NF-κB/Rel dimers (and
interactions with other transcription factors and co-factors) they can either
activate or inhibit transcription of genes. Activation of the NF-κB/Rel pathway
is integral to the production and release of Ig from B cells in response to
bacterial insult and is required for B-cell activation and differentiation in
response to a T-cell activating signal, such as through the CD40 receptor.
Both Cytosine-phosphate-Guanine (CpG)-oligodeoxynucleotides and
lipopolysaccharide (LPS), which are associated with bacterial DNA and
bacterial cell walls respectively, activate B cells in a T-cell independent
manner and lead to the production of Ig.
Results from recent research have demonstrated protein interactions
between the AhR and NF-κB/Rel proteins, specifically RelA and RelB.
Interaction with the AhR may alter the DNA binding profile of specific NFκB/Rel dimers and therefore have an impact on genes that are
transcriptionally regulated by NF-κB/Rel proteins (Tian, Ke et al. 1999; Vogel,
Sciullo et al. 2007). Functional Ig production is dependent on the expression
of the Ig heavy chain that is partially under the transcriptional regulation of the
3’Ig heavy chain regulatory region (3’IghRR) (Klein, Sablitzky et al. 1984;
Wabl and Burrows 1984; Singh and Birshtein 1993; Madisen and Groudine
1994; Saleque, Singh et al. 1997). Within the 3’IghRR, both κB and DRE
sites have been identified, providing a potential transcriptional target of NF-κB
2

and AhR proteins (Sulentic, Holsapple et al. 2000). Interestingly, treatment of
B cells with TCDD has demonstrated an inhibition of Igh transcription and the
transcriptional activity of the 3’IghRR (Sulentic and Kaminski 2011),
suggesting that the 3’IghRR is a transcriptional target of TCDD and mediates
the effect of TCDD on Ig. These transcriptional inhibitions may, in part, be
mediated by an interaction between the AhR and NF-κB/Rel proteins, which
could disrupt NF-κB/Rel binding, alter the NF-κB/Rel binding profiles within
the 3’IghRR, and/or directly modulate transcriptional control through direct
AhR/DRE binding. The central hypothesis of this proposal is that TCDDinduced inhibition of 3’IghRR activation is mediated by an interaction between
the AhR and NF-κB/Rel proteins. Understanding how the 3’IghRR becomes
transcriptionally active is of great importance as the 3’IghRR has been
associated with human pathologies such as Burkitt’s lymphoma, IgA
nephropathy, Celiac disease, systemic sclerosis, dermatitis herpetiformis,
psoriasis arthritis, and plaque psoriasis (Taub, Kirsch et al. 1982; Aupetit,
Drouet et al. 2000; Frezza, Giambra et al. 2004; Frezza, Giambra et al. 2007;
Cianci, Cammarota et al. 2008; Cianci, Giambra et al. 2008). Furthermore,
understanding how TCDD modulates the expression of the 3’IghRR after B
cell activation is of toxicological significance to a broad range of chemicals
known to modulate the AhR signaling pathway and may provide
pharmaceutical approaches to managing diseases associated with the
3’IghRR.
.
3

TCDD and relevance to human health
Dioxins are persistent environmental toxins produced during the
combustion of organic materials in the presence of chlorine (USEPA 2000;
Hays and Aylward 2003). Dioxins have been released into the environment
due to pulp bleaching in paper mills, the production of polyvinyl chloride
(PVC) plastics, incineration of municipal trash and medical waste, and
backyard burning of trash and foliage. Dioxin-like compounds fall under a
class of chemical structures known as halogenated aromatic hydrocarbons
(HAH) and include dibenzofurans, and certain polychlorinated biphenyls
which exist as persistent environmental toxins in complex mixtures (Okey
1990; Safe 1995). 2,3,7,8 Tetrachlorodibenzo-p-dioxin (TCDD) is considered
the most potent of the HAH environmental pollutants collectively known as
dioxins (Franc, Pohjanvirta et al. 2001). Although there has been a gradual
decrease in environmental concentrations and human body burdens of dioxin
(Aylward and Hays 2002; Hays and Aylward 2003), the U.S. Environmental
Protection Agency (EPA) suggested in its Dioxin Reassessment (2000) that
the current average human body burdens of dioxins are 25 ppt or 25 pg
TCDD Equivalent Quantity (TEQ/g lipid). However, the body burden may be
up to three times higher (75 TEQ/g lipid) than the average burden and can be
correlated to a diet with a high fat intake (USEPA 2000). Exposures to TCDD
in non-occupational settings are almost all from the consumption of
contaminated food sources (Lorber, Patterson et al. 2009). As dioxins are
highly lipophilic, environmentally persistent, and bioaccumulate, the
4

concentration of TCDD increases in each species as it progresses through
each trophic level. Concentration levels as low as 0.01ppt measured in a
water column can be biomagnified to concentration levels in excess of 110 pg
TEQ when measured in the species at the highest trophic level (USEPA
2000). Since humans are at the highest trophic level, the potential to
bioaccumulate biologically significant concentrations of dioxin is greatly
enhanced.
Dioxin exposures have generated considerable public concern in the
U.S. since the late 1970’s with evacuations from Love Canal in Niagara Falls,
NY, Times Beach, MD, and from Seveso, Italy, as well as multiple exposures
to dioxin-contaminated Agent Orange during the Vietnam War (Schecter,
Quynh et al. 2006; Consonni, Pesatori et al. 2008). There have been several
documented and unexpected dioxin contaminations of the food supply which
are compounded by uncertainties associated with the possible sources of
dioxin (Amakura, Tsutsumi et al. 2003; Hays and Aylward 2003; Mandal
2005). Human populations exposed to high levels of dioxin are subjected to
alterations in liver function and tend to exhibit the hallmark response of
chloracne (acne-like eruption of pustules, blackheads, and cysts) as seen in
the more recent poisoning of the Ukrainian President, Viktor Yushchenko in
2004 (Neuberger, Landvoigt et al. 1991; Sweeney, Calvert et al. 1997;
Mandal 2005; Linden, Lensu et al. 2010). Long term effects from exposures to
TCDD in Seveso, Italy demonstrated an increase in multiple myeloma’ and
myeloid leukemias (Pesatori, Consonni et al. 2009). TCDD has been utilized
5

for the majority of dioxin research and has been studied with a greater
intensity than other environmental pollutants because TCDD is highly active
at low concentrations (Whitlock 1990). At low doses, TCDD has been
reported to produce a diverse spectrum of adverse effects in animal models
including cancer, reproductive issues, developmental issues, immunologic
suppression, endocrine disruption, and death (Birnbaum and Tuomisto 2000).
The biological effects following exposure to TCDD has been actively
researched for more than thirty years, generating a wealth of data. These
data show that toxic outcomes to TCDD exposure are species, strain/substrain, sex, age, dose, and duration dependent. Extensive research has
identified that AhR may be responsible for most of the TCDD-induced effects
(Poland and Glover 1980; Okey, Riddick et al. 1994; Fernandez-Salguero,
Hilbert et al. 1996; Tuomisto, Viluksela et al. 1999; Linden, Lensu et al. 2010).
To date, there is not an established “no observable effect level”
(NOEL) for TCDD burdens, and the current human body burdens may be well
within the range to induce adverse health effects ranging from endocrine
disruption, enzyme induction, hepatomegaly, immunomodulation, chloracne,
epithelial hyperplasia, and teratogenesis (USEPA 2000; Aylward and Hays
2002; Paustenbach and Board 2002; Hays and Aylward 2003). It has been
suggested that the non-cancer effects of dioxin may be a more urgent threat
to human health (Stone 1994). Additionally, alterations in immune function
have been observed in virtually every vertebrate species tested, and often
occur at doses that fail to produce obvious signs of toxicity (Holsapple,
6

Snyder et al. 1991; Kerkvliet 2002; Sulentic and Kaminski 2011).
Furthermore, multiple studies using animal models of human disease have
demonstrated an inhibition of immune responses and increased susceptibility
to bacterial, viral, and parasitic infection after host exposure to TCDD. Host
resistance studies beginning in the mid-1970’s through the present have
demonstrated an increased susceptibility of TCDD-exposed mice and rats to
gram-negative bacteria such as Salmonella or Escherichia coli (Thigpen,
Faith et al. 1975; Vos, Kreeftenberg et al. 1978; Thomas and Hinsdill 1979;
Hinsdill, Couch et al. 1980), gram-positive bacteria such as Streptococcus
pneumoniae (White, Lysy et al. 1986), viral infections from herpes simplex
type II strain 33 virus and influenza (Clark, Sweeney et al. 1983; White, Lysy
et al. 1986; Lawrence, Warren et al. 2000; Warren, Mitchell et al. 2000), and
parasitic infections from Plasmodium yoelii 17 XNL (Tucker, Vore et al. 1986).
Exposure to TCDD inhibits T-cell dependent responses as shown by delayed
hypersensitivity responses and reduced generation of cytotoxic T
lymphocytes (Moos, Baecher-Steppan et al. 1994). Antigen presenting cells
(APC) have been shown to have diminished capability to express common
lymphocyte activation markers such as CD86 as seen in both spleen B cells
and macrophage cells following exposure to TCDD (Prell and Kerkvliet 1997).
Additionally, TCDD-induced inhibition of B-cell function (i.e. cellular
proliferation, Ig expression and secretion) has been demonstrated using
various cellular and in vivo models (Morris, Karras et al. 1993; Karras and
Holsapple 1994; Masten and Shiverick 1995; Sulentic, Holsapple et al. 1998;
7

Sulentic and Kaminski 2011). Taken together, the immune system is a
sensitive target of TCDD-induced suppression. As B-cells are directly
suppressed by TCDD (Sulentic and Kaminski 2011) and exposure to TCDD
directly impacts an adaptive immune response, the focus of the current
research was to further investigate the mechanisms by which TCDD impacts
Ig expression.

B-cell activation
B cells are lymphocytes that play a primary role in the humoral immune
system. The principal functions of B cells are to make antibodies against
antigens, perform as antigen presenting cells APCs, and develop into
memory B cells after activation by an antigen interaction. Exposure of the
antigen to a B cell elicits an activation signal that induces clonal proliferation
followed by differentiation into antibody secreting cells (Figure 1). B cells can
be activated through an interaction between an antigen and the B-cell
receptor (BCR), activation through any one of the 10 identified Toll-Like
Receptors (TLR’s), co-stimulation with the BCR and an engaged TLR, costimulation with an antigen and CD-40 ligand (simulates a T-cell interaction),
cytokines, and/or multiple combinations of these activation pathways.
B-cell activation through TLRs was recently found to play an important
role in the first line of host defense by the recognition of microbial products.
TLRs are capable of recognizing conserved pathogen-associated molecular
8

patterns (PAMPs) (Schmausser, Andrulis et al. 2004; Peng 2005), and
activate B cells. Additionally, TLRs and the B Cell Receptor (BCR) have been
shown to synergize to induce class switch in T-cell independent activation of
B cells to enhance differentiation and antibody response (Pone, Zan et al.
2010). TLR4 is a membrane-bound protein expressed on the surface of B
cells complexed with membrane-bound Radio Protective 105 (RP105)
protein. The TLR4/RP105 heterodimer is a fundamental component required
for the recognition of lipopolysaccharide (LPS) and T-cell independent
activation of B cells (Hoshino, Takeuchi et al. 1999). TLR7, TLR8, and TLR9
are not on the cell surface but rather are associated with the endoplasmic
reticulum. TLR7 and TLR8 signaling is initiated when ssRNA associates with
TLR7 and TLR8. Resiquimod (R848) is an immune response modifier used in
skin lesion treatment and as an adjuvant to increase the effectiveness of
vaccines. R848 functions as an agonist to TLR7 and TLR8 (Lanzavecchia
and Sallusto 2007). TLR9 signaling is triggered by an interaction with
hypomethylated/unmethylated cytosine-phosphate-guanine (CpG)oligodeoxynucleotides (ODN) which is consistent with double stranded
bacterial DNA (Krieg, Yi et al. 1995; Hacker, Mischak et al. 1998; Hartmann,
Weeratna et al. 2000; Hemmi, Takeuchi et al. 2000; Bauer, Kirschning et al.
2001; Takeshita, Leifer et al. 2001; Krieg 2002). Vertebrate DNA has CpG in
a form that is not only highly methylated but also has a suppressed
occurrence such that CpGs are found only about one quarter as often as
would be predicted if base utilization was random (Krieg 2000). B-cell
9

activation by LPS, CpG, or R848 through TLR4, TLR9, or TLR7 and TLR8,
respectively, B cells can also be activated through a membrane-bound
receptor on B cells known as CD40. B-cell activation through CD40 with
CD40 ligand (CD40L) which is expressed on the surface of T cells may
require an additional stimulus directed against a TLR or the B cell Receptor, a
membrane-bound Ig that can bind antigen. Proliferation, up-regulation of
Cluster of Differentiation 86 (CD86), increased secretion of Ig and cytokines,
and the cessation of spontaneous programmed cell death are all hallmarks of
B cell activation (Miyake, Yamashita et al. 1994; Krieg 1995; Yi, Hornbeck et
al. 1996; Chan, Mecklenbrauker et al. 1998; Krieg 2002).
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Figure 1. B-cell activation
Exposure of the antigen to a B cell elicits an activation signal that induces
clonal proliferation followed by differentiation into antibody secreting cells. B
cells can be activated through an interaction between an antigen and the Bcell receptor (BCR), activation through any one of the 10 identified Toll-Like
Receptors (TLR’s), co-stimulation with the BCR and an engaged TLR, costimulation with an antigen and CD-40 ligand (simulates a T-cell interaction),
cytokines, and/or multiple combinations of these activation pathways.
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NF-κB signaling pathway
Many similarities exist between the TLR4, TLR7, TLR8, and TLR9
signaling pathways (Figure 2). For example, they all initiate intracellular
signaling through either the Toll/interleukin 1 receptor (IL-1R)-Myeloid
Differentiation primary response gene 88 (MyD88) or the Toll/IL-1R domaincontaining adaptor protein (TIRAP) pathway. IL-1R provides a scaffold for the
recruitment of the adaptor molecule MyD88 to form a dimer and recruit the
serine/threonine kinase of the interleukin-1 receptor-associated kinase (IRAK)
family. Autophosphorylation of IRAK leads to TNF receptor associated factor
6 (TRAF6) adapter protein recruitment. After TRAF6 has complexed with
IRAK, the TRAF6/IRAK complex disengages from the MyD88/IL-1R dimer.
The TRAF6/IRAK complex then interacts with another protein complex
consisting of TAK1-TAB1-TAB2 initiating phosphorylation and activation of
IκB kinase (IKK). Phosphorylation of IKK leads to the phosphorylation and
degradation of IκBα which ultimately induces rapid NF-κB activation (Chen
and Goeddel 2002). CD40 activation combined with an antigen-induced BCR
activation signaling can be transduced through the TRAF6 pathway (Zhu,
Ramirez et al. 2002). Regardless of the initial activation signal, these
signaling cascades result in the phosphorylation of Kinase (IKK). In the
classical (canonical) pathway, NF-κB/Rel proteins are bound and inhibited by
IκB proteins. IKK phosphorylates IκBα/β, ultimately leading to proteasomal
degradation of IκBα/β leading to the nuclear translocation of NF-κB/Rel
12

proteins, RelA-p50, and to a lesser extent c-Rel-p50 (Akira and Takeda
2004). In the alternative activation pathway, IKK phosphorylation of NF-κB2
p100 leads to ubiquitination and proteasomal processing to NF-κB2/p52
creating transcriptionally active NF-κB p52/RelB. Interestingly, of the NFκB/Rel proteins, only RelB cannot form a homodimer, and has been shown to
interact with RelA, forming a transcriptionally inactive complex (Marienfeld,
May et al. 2003). Upon NF-κB activation, NF-κB/Rel dimers translocate to the
nucleus bind to their respective κB binding sites and exert their transcriptional
effects (Figure 3) (Chen and Goeddel 2002). Interestingly, the NF-κB dimers
are sensitive to the manner in which the B cell is activated. In LPS-activated B
cells, RelA-p50 is the primary NF-κB/Rel protein found in the nuclear fraction;
however, activation through CD40 shifts the NF-κB/Rel nuclear composition
from an abundance of RelA (p65) to RelB (p68) and c-Rel (p75) (Neumann,
Wohlleben et al. 1996). NF-κB/Rel activation is critical to B-cell maturation
(Franzoso, Carlson et al. 1997), proliferation (Prendes, Zheng et al. 2003),
and differentiation into Ig-secreting plasma cells (Liou, Sha et al. 1994).
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Figure 2. Toll-like receptor signaling pathway
TLR activation is initiated through either the IL-1R- MyD88 or the TIRAP
pathway. IL-1R provides a scaffold for the recruitment of the adaptor molecule
MyD88 to form a dimer and recruit the serine/threonine kinase of the IRAK
family. Autophosphorylation of IRAK leads TRAF6 recruitment. After TRAF6
has complexed with IRAK, the TRAF6/IRAK complex disengages from the
MyD88/IL-1R dimer. The TRAF6/IRAK complex then interacts with another
protein complex consisting of TAK1-TAB1-TAB2 initiating phosphorylation of
kinase IKKs. Phosphorylation of IKK leads to the phosphorylation and
degradation of IκBα which ultimately induces rapid NF-κB activation.

14

Figure 3. NF-κB Signaling Pathway
Classical activation of the NF-κB/Rel pathway is dependent upon upstream
signal transduction that leads to the phosphorylation of the IκBα regulatory
protein at Serines 32 and 36. Upon phosphorylation of the IκBα, IκBα is
ubiquitylated, and the IκBα is subsequently targeted for proteolytic
degradation. After IκBα degradation, NF-κB/Rel is liberated and is
transcriptionally active.
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AhR and B-cell dysfunction
Through early cell-type fractionation studies, B cells were identified as
a direct target of TCDD-induced antibody suppression (Holsapple, Dooley et
al. 1986; Dooley and Holsapple 1988). Several in vivo and in vitro studies
have demonstrated that exposure to TCDD inhibits the process of B-cell
differentiation into Ig secreting cells (North, Crawford et al. 2009). Extensive
research has identified that the AhR, may be responsible for most of the
TCDD-induced effects (Poland and Glover 1980; Okey, Riddick et al. 1994;
Fernandez-Salguero, Hilbert et al. 1996; Tuomisto, Viluksela et al. 1999;
Linden, Lensu et al. 2010). However TCDD may generate intracellular
reactive oxygen species contributing to the toxicological consequences
(Reichard, Dalton et al. 2005). Research using a cellular model that consisted
of two surface Ig+ (mature) B cell lines, the CH12.LX and the BCL-1, which
differ in their expression of the AhR and in their sensitivity to TCDD,
demonstrated that although both cell lines are significantly activated by LPS,
only the CH12.LX (AhR expressing) had a marked inhibition of LPS-induced
IgM secretion. In contrast, the LPS-induced IgM secretion from the AhRdeficient BCL-1 cells was unchanged by co-treatment with TCDD (Sulentic,
Holsapple et al. 2000). However, these studies are somewhat limited by the
comparison of two different cell lines that likely have differences distinct from
AhR expression. Later studies with the AhR-null mice demonstrated a similar
AhR-dependency in TCDD-induced suppression of B-cell differentiation
(Vorderstrasse, Steppan et al. 2001). Additionally, studies using human
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primary B cells have demonstrated an inhibition of cellular proliferation
induced by co-stimulation with both CD40L (simulates a T cell interaction) and
CpG (oligodeoxynucleotides containing hypomethylated or unmethylated
CpG) when co-treated with a known ligand for the AhR (Allan and Sherr
2005). Sulentic et al. (Sulentic, Holsapple et al. 2000), demonstrated that in
addition to IgM secretion, TCDD strongly inhibits µ heavy chain expression in
the CH12.LX B cells, which also seems to be AhR-dependent, and profoundly
inhibits LPS-induced activation of the 3’IghRR (Sulentic, Zhang et al. 2004).
The immunoglobulin heavy chain locus (Igh), which encodes the functional
heavy chain protein of membrane-bound and secreted (antibody)
immunoglobulin, is under the regulation of the 3’IghRR. The 3’IghRR has
been shown to have AhR binding sites within the hs1,2 and the hs4
enhancers as reviewed later in the manuscript.
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AhR signaling pathway
The mechanism thought to mediate the biological effects of TCDD is
the AhR signaling pathway. The AhR is located in the cytoplasm (Figure 4)
and exists as one component of a complex composed of two molecules of a
90-kDa heat shock protein (hsp90) (Denis, Gustafsson et al. 1988;
Wilhelmsson, Cuthill et al. 1990), a 38-kDa immunophilin-related protein
(XAP2), and p23 (Shetty, Bhagwat et al. 2003). Although there are multiple
AhR activators including TCDD, the endogenous ligand remains elusive.
When TCDD diffuses through the outer cell membrane, it binds the AhR with
high affinity leading to the disassociation of XAP2, which exposes a nuclear
transport signal (Kazlauskas, Sundstrom et al. 2001). Upon nuclear
translocation, AhR disassociates from the hsp90 molecules and p23 and
dimerizes with the AhR nuclear translocator protein (ARNT) (Pollenz 1996).
The TCDD-AhR-ARNT heterodimer then binds to specific DNA sequences
referred to as dioxin responsive elements (DRE) and modulates transcription
of TCDD sensitive genes (Swanson 2002). The activation of AhR upregulates a number of drug metabolizing enzymes including the well
characterized induction of cytochrome P450.
Although the majority of research investigating the role of the AhR has
focused primarily of the toxic effects associated with ligand activation of the
AhR, there are increasing efforts to elucidate the physiological role of the
AhR. That said, there is still much debate as to the endogenous ligand for the
AhR. Nguyen and Bradfield (Nguyen and Bradfield 2008), have speculated
18

that ligand binding specificity of the AHR does not differ significantly across
species, signifying that the evolutionary stressor influencing ligand specificity
of the AHR is an endogenous compound. The physiological significance of
the AhR was initially assed through the investigation of AhR knockout (KO)
animal models. The phenotypes of newborn AhR KO mice demonstrate
alterations in vascularity (Lahvis, Lindell et al. 2000), 40-50 percent neonatal
lethality rate, inflammation of the bile ducts, and, 80 percent depletion of
splenocytes (Fernandez-Salguero, Pineau et al. 1995), fewer lymphoid cells
in the peripheral lymph nodes, increased failure to thrive, significantly reduced
CyP1a1, CyP1a2, and non- inducible ethoxyresorufin-O-deethylase (EROD)
activity (Lahvis and Bradfield 1998). Interestingly, the phenotypes of AhR KO
mice and rats demonstrate uniquely and distinct difference in alterations in
hepatic function, bilateral renal dilation, bilateral, ureter dilation, persistent
haloid arteries in the eye, and patent ductus venosus of the liver suggesting
species-dependent tissue development (Harrill, Hukkanen et al. 2013).
Indigoids (indigo and indirubin) have been suggested to be endogenous
AhR ligands, and have been found in human urine and bovine serum (Adachi,
Mori et al. 2001). Additional potential endogenous AhR ligands are 2-(1’Hindole-3’-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) (Song,
Clagett-Dame et al. 2002), arachidonic acid metabolites ((Kroetz and Zeldin
2002), heme metabolites (Phelan, Winter et al. 1998), and tryptophan
metabolites (Heath-Pagliuso, Rogers et al. 1998). Based upon a review of the
current literature, the endogenous ligand for the AhR still remains elusive.
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Recent research has demonstrated that the AhR not only dimerizes to
ARNT, but may also complex with a myriad of other transcription factors and
alter functional transcription of genes. Specifically, the AhR has been shown
to interact with activator protein 1 (AP-1), specificity protein 1 (Sp1), and
nuclear factor-κB (NF-κB)/Rel transcription factors (Kobayashi, Sogawa et al.
1996; Tian, Ke et al. 1999; Kim, Gazourian et al. 2000; Suh, Jeon et al. 2002;
Tian, Rabson et al. 2002; Vogel, Sciullo et al. 2007). Of particular interest, are
the NF-κB/Rel transcription factors that regulate genes responsible for both
the innate and adaptive immune response. Upon B-cell activation, NF-κB/Rel
becomes activated through distinct signaling components. The activation and
nuclear translocation of NF-κB/Rel proteins are critical to B-cell activation and
Ig expression. Moreover, a TCDD-induced AhR/NF-κB/Rel interaction may, at
least partially, mediate the well-documented inhibition of B cell activation
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Figure 4. AhR signaling pathway
When AhR binds a ligand, it undergoes conformational changes and
dissociates from the cytosolic protein X-associated protein (XAP2). The AhR
then translocates into the nucleus, and dissociates from heat shock proteins,
HSP90 and p23. The AhR forms a complex with the AhR nuclear translocator
(ARNT). The TCDD/AhR/ARNT complex binds a dioxin responsive element
(DRE). After binding the DRE, transcription of AhR sensitive genes can occur
(such as transcription of Cyp1A1).
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following TCDD exposure identified in both in vivo and in vitro studies.
Furthermore, within the 3’IghRR, the hs1,2 and hs4 enhancers have binding
sites for both the AhR and NF-κB/Rel. More significantly, in the hs4 enhancer
has an AhR and NF-kB/Rel binding site that overlap.

Interactions between the AhR and NF-κB/Rel proteins
When both the AhR and the NF-κB/Rel (RelA, RelB, and c-Rel) are
activated, these signaling pathways have been shown to interact (Kim,
Gazourian et al. 2000; Sherr 2004; Vogel, Sciullo et al. 2007). NF-κB/Rel has
been shown in both the murine hepatoma Hepa1c1c7 and the monkey kidney
tissue derived COS-7 cell line models to physically interact with TCDDactivated AhR leading to an AhR-mediated repression of reporter plasmids
under κB regulation (Tian, Ke et al. 1999; Tian, Rabson et al. 2002).
However, Kim et al. demonstrated that an AhR and RelA interaction
functionally cooperate in a human breast cancer Hs578T cell line to increase
c-myc gene expression (Kim, Gazourian et al. 2000). Additionally, Vogel et al.
demonstrated that AhR and RelB not only associate, but over-expression of
RelB can drastically increase DRE reporter activity (Vogel, Sciullo et al.
2007). These interactions may not only alter the binding of NF-κB to its
respective κB binding site but may modulate the binding of the AhR to DREs
(Tian, Ke et al. 1999). Additionally, Sulentic et al. demonstrated through
mutational analysis in a B-cell line model that both the κB and the identified
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DRE site were critical for synergistic activation of an enhancer within an
immunoglobulin regulatory region known as the hs4 enhancer (Sulentic,
Zhang et al. 2004). Taken together, the physical interactions between AhR
and NF-κB/Rel may alter the expression of genes that are under NF-κB/Rel
and/or AhR transcriptional regulation and likely lead to an alteration in cellular
function.

Immunoglobulin heavy chain regulation and the 3’IghRR
The Igh gene locus contains multiple regulatory domains including
variable heavy chain promoters, a heavy chain (VH) promoter; intronic or µ
enhancer (Eµ); germline promoters upstream of each constant region (CH);
and a regulatory region 3’ of the constant regions which contains at least four
enhancer domains (hs3a, hs1,2, hs3b and hs4) collectively named the
3’IghRR (Figure 5). Although the murine 3’IghRR is approximately 16 kb
downstream of Cα, (Dariavach, Williams et al. 1991) the 3’IghRR has been
shown to directly associate with the Eµ within the context of chromatin (Ong,
Stevens et al. 1998). Activation of the 3’IghRR is correlated with transcription
of the rearranged Ig heavy chain gene, Ig secretion, and class switch
recombination (Klein, Sablitzky et al. 1984; Wabl and Burrows 1984; Singh
and Birshtein 1993; Madisen and Groudine 1994; Saleque, Singh et al. 1997).
Within the 3’IghRR, there are multiple DNA binding sites for several
transcriptional factors including AP-1,Oct, B-cell Specific Activator Protein
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Figure 5. Basic Ig structure and murine Igh allele
Basic structure of an Ig antibody (top) produced by a B cell. The Ig heavy
chains are the direct product of transcription of the Igh locus under the
regulation of the 3’IghRR. VH, variable heavy chain promoter; Eµ, intronic or µ
enhancer; open rectangles, germline promoters upstream of each CH region.

24

(BSAP), and NF-κB/Rel (Arulampalam, Grant et al. 1994; Grant, Andersson
et al. 1996; Michaelson, Singh et al. 1996; Saleque, Singh et al. 1999; Kanda,
Hu et al. 2000; Khamlichi, Pinaud et al. 2000; Stevens, Ong et al. 2000;
Zelazowski, Shen et al. 2000). Additionally, Sulentic et al. (Sulentic,
Holsapple et al. 2000), identified binding of both the AhR to DREs and NFκB/Rel proteins to κB sites in hypersensitive (hs) enhancers within the
3’IghRR (Figure 6). The results from this study demonstrated that treatment of
CH12.LX (AhR responsive) B cells with TCDD leads to an increase in the
binding of AhR and ARNT proteins to DRE-like sites in both the hs1,2 and
hs4 enhancers. These data suggest that the AhR/DRE may be involved in Ig
inhibition through direct interactions within the 3’IghRR.
Furthermore, additional luciferase studies demonstrate a sensitive and
profound inhibition by TCDD of LPS-induced 3’IghRR activity (Sulentic, Kang
et al. 2004). Interestingly, neither LPS alone nor TCDD alone induce hs4
activity, yet LPS co-treated with TCDD produced a synergistic activation of
hs4. In addition, a chromatin immunoprecipitation (ChIP) assay confirmed
TCDD-inducible AhR binding to the hs4 enhancer domain and site-directed
mutation of the hs4 DRE and/or κB decreased the effect of TCDD and LPS on
hs4 activity suggesting the synergistic activation by a co-treatment of TCDD
and LPS was dependent on binding to both the DRE and κB. Collectively,
these data demonstrate TCDD-mediated modulation of the 3’IghRR, which
may be produced, at least in part, through transcriptional regulation by the
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Figure 6. hs1,2 and hs4 enhancer DRE and κB binding sites
DRE and κB binding sites within the hs1,2 and hs4 for the AhR and the NFκB/Rel transcription factors.
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AhR. EMSA-Western analysis of the CH12.LX B cells demonstrated TCDDinduced binding of the NF-κB/Rel proteins RelA, c-Rel, RelB, and p50 to the
κB binding motif within the hs4 enhancer. However, in the BCL-1 B cells
(AhR non-responders), EMSA-Western analysis also revealed TCDD-induced
binding of c-Rel, RelA, and RelB to the hs4 κB motif. These results suggested
an AhR-independent mechanism for the induction of c-Rel, RelA, and RelB
binding by TCDD but perhaps an AhR-dependent induction of p50 binding.
These results may suggest a change in NF-κB/Rel binding profile within the
hs4 enhancer when the AhR is active.
There is a cooperative interaction between the enhancers within the
3’IghRR in their overall regulation of the IgH gene (Ong, Stevens et al. 1998).
Interestingly, there is a dichotomy that exists between the activation states of
individual hs4 and hs1,2 enhancers within the 3’IghRR and the overall
activation of the 3’IghRR (Michaelson, Singh et al. 1996). The binding of κB,
BSAP, and OCT can be both a positive regulator of hs4 activity and a
negative regulator of hs1,2 activity (Michaelson, Singh et al. 1996). DRE
binding also has a similar dichotomy in the effect on hs4 activity versus hs1,2
(Fernando, Ochs et al. 2012) and 3’IghRR(Sulentic, Kang et al. 2004).
Consistent with the previous findings, treatment with TCDD was shown to
inhibit LPS induced hs1,2 activation and synergistically hs4 (Sulentic, Zhang
et al. 2004). Taken together, these results suggest that the inhibition of IgM
secretion by TCDD may require the induction of both DRE and κB binding
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within the 3’IghRR as identified in the hs4 enhancer. Because the DRE and
κB binding sites overlap in the hs4, binding to either the DRE or κB motif may
facilitate or stabilize binding to the other motif.
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CHAPTER 2. HYPOTHESIS AND SPECIFIC AIMS

Significance of proposed research
Altered regulation of the 3’IghRR by environmental toxins may pose a
significant health threat to human health by limiting the ability of the immune
system to respond to insult. Additionally, the 3’IghRR has been associated with
human pathologies such as Burkitt’s lymphoma, IgA nephropathy, Celiac
disease, systemic sclerosis, dermatitis herpetiformis, psoriasis arthritis, and
plaque psoriasis (Aupetit, Drouet et al. 2000; Frezza, Giambra et al. 2004;
Frezza, Giambra et al. 2007; Cianci, Cammarota et al. 2008; Cianci, Giambra et
al. 2008). Comparisons between the mouse and human IgH locus and the
3’IghRR, have identified structural differences and similarities including 1) unlike
the mouse, the human locus has a large duplication at the 3’ end of IgH locus
which consists of several repeated constant region genes and a repeated
3’IghRR; 2) the human 3’IgHRR (hs3, hs1,2 and hs4 homologous to mouse
hs3a, hs1,2, hs4) is located 3’ of both Cα1 and Cα2 but two hs1,2 enhancers are
inverted with respect to each other; and 3) mouse and human 3’IghRR has an
overall core similarity in sequence (approximately 500 bp) of approximately 65%
(Figure 5) (Chen and Birshtein 1997; Mills, Harindranath et al. 1997; Pinaud,
Aupetit et al. 1997). Close examination of the mouse and human hs4 enhancer
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sequences (Guglielmi, Truffinet et al. 2004) identified highly conserved
sequences for the overlapping DRE and κB binding motifs with 10 of 11
identical nucleotides for the DRE sequences, however, as the core sequence
is not conserved there may be a possibility that the AhR will not bind the
human hs4. Additionally, there are 9 of 10 identical nucleotides for the hs4 κB
sequences. Within the hs1,2 enhancer (Denizot, Pinaud et al. 2001), the DRE
site is also fairly well conserved with 8 of 11 nucleotides identical including a
consensus core DRE (GCGTG). The evolutionarily conserved close proximity
of the κB and DRE binding motifs in the human hs1,2 and the overlapping κB
and DRE binding motifs in the hs4 enhancers may implicate an interaction
between the AhR and NF-κB/Rel proteins, supporting a role in an AhR and
NF-κB/Rel mediated inhibition of the 3’IghRR. As the 3’IghRR is highly
correlated with the secretion of Ig, and with multiple human disease
processes, understanding how the 3’IghRR is modulated after exposure to
dioxin is of great potential relevance to human health.
The current proposal will explore the role of the AhR and NF-κB/Rel
proteins in TCDD-induced modulation of the 3’IghRR which may, at least
partially, mediate the effects of TCDD on mouse B-cell function through an
inhibition of Igh transcription and Ig secretion. As described earlier, current
and ongoing research in our lab has indicated that the 3’IghRR is a sensitive
target of the suppressive effects of TCDD. Understanding how TCDD
modulates transcription of the 3’IghRR is of toxicological significance to a
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broad range of dioxin-like chemicals and may provide pharmaceutical
approaches to managing diseases associated with the 3’IghRR.

Hypothesis
Immunoglobulins (Ig) are essential for maintaining immunity against a
wide variety of pathogens. However, little is known regarding the impact of
chemicals or disease states on Ig gene expression. Research has shown
that 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a well-known suppressor of
B-cell differentiation, potently inhibits activation of the transcriptional
regulatory region (known as the 3’IghRR) found downstream of the Ig heavy
chain (Igh) locus. In addition to its proposed role in Ig gene expression, the
3’IghRR has also been associated with specific human pathologies including
Burkitt’s lymphoma, IgA nephropathy, Celiac disease, systemic sclerosis,
dermatitis herpetiformis, psoriasis arthritis, and plaque psoriasis. Many of the
toxic effects of TCDD and related chemicals have been attributed to changes
in gene expression resulting from the activation of the aryl hydrocarbon
receptor (AhR) which subsequently binds to dioxin-responsive elements
(DRE) in affected genes. We have detected binding of AhR to DRE sites
within two enhancers of the 3’IghRR, hs1,2 and hs4, and find that these DRE
sites are closely associated with NF-κB binding motifs. We hypothesize that
TCDD represses 3’IghRR activation through an AhR-dependent shift in
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the NF-κB/Rel protein complexes binding within the hs1,2 and hs4
enhancers. The following specific aims (SA) will test this hypothesis.

Specific Aims
Specific Aim 1: Determine if when activated by alternate B-cell
stimuli, TCDD inhibits the 3’IghRR. In the CH12.γ2b-3′IghRR cell line, we
will evaluate the transcriptional effect of TCDD on the 3’IghRR in the
presence of different stimuli co-treated with TCDD. This aim will test the
hypothesis that TCDD is a general inhibitor of 3’IghRR activation and of Ig
expression regardless of the activation stimuli. Additionally, we will determine
if activation of different TLRs are equally affected by TCDD.
Specific Aim 2: Determine the TCDD and LPS-induced binding
profile of the AhR and NF-κB/Rel proteins within the hs4 and hs1,2
enhancers. In CH12.LX cells and splenocytes derived from B6C3F1 female
mice, we will evaluate the binding of NF-κB/Rel proteins (RelA and RelB,)
within the hs1,2 and hs4 enhancers by chromatin immunoprecipitation (ChIP)
analyses. This aim will test the hypothesis that treatment with TCDD results
in both qualitative and quantitative shifts in proteins bound to the κB sites of
the hs1,2 and hs4 enhancers.
Specific Aim 3: Determine whether the AhR and NF-κB/Rel
proteins mediate TCDD’s repressive effect on 3’IghRR activation. Using
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repression of NF-κB/Rel proteins and chemical inhibition of the AhR, we will
test the hypothesis that both the AhR and NF-κB/Rel proteins are required for
the TCDD-induced inhibition of LPS-induced 3’IghRR activation. To this end,
we will utilize the CH12.LX variants; the CH12.IκBαAA that expresses the
IκBα super-repressor protein to inhibit NF-κB activation, and the CH12.γ2b3′IghRR cell line that stably expresses a γ2b transgene regulated by the
3’IghRR.
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CHAPTER 3. METHODS AND MATERIALS

Chemicals and Reagents
TCDD in 100% dimethyl sulfoxide (DMSO) was purchased from
AccuStandard Inc. (New Haven, CT). The certificates of product analysis stated
the purity of TCDD to be 99.1%. IPTG (isopropyl β-D-1-thiogalactopyranoside),
LPS (Escherichia coli), and DMSO were purchased from Sigma Aldrich
(Milwaukee, WI). IPTG and LPS were dissolved in water and 1xPBS,
respectively. The AhR antagonist CH-223191 was purchased from Calbiochem
(San Diego, CA) and dissolved in 100% DMSO. Resiquimod (R848) was
purchased from Enzo Life Sciences (Farmingdale, NY) and dissolved in 100%
DMSO. Cytosine-phosphate-guanine (CpG)-oligodeoxynucleotides (ODN) (5’TCCATGACGTTCCTGACGTT -3’) was purchased from Eurofins MWG Operon
(Huntsville, Alabama) and dissolved in RNase and DNase free water.

Cell Lines
The CH12.IκBαAA B-cell line (IgM+) was developed and generously
provided by Dr. Gail Bishop (Hsing and Bishop 1999) and is a variant of the
parental CH12.LX cell line (IgA+) (Hsing and Bishop 1999), which was derived
from the murine CH12 B-cell lymphoma (Arnold, LoCascio et al. 1983) in B10.H-
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2aH-4bp/Wts mice (B10.A x B10.129). The CH12.IκBαAA cell line stably
expresses an IPTG-inducible, degradation resistant IκBα super-repressor
protein (IκBαAA), which sequesters NF-κB/Rel proteins in the cytoplasm
(Hsing and Bishop 1999). The CH12.γ2b-3′IghRR cell line (IgA+) was
generated from CH12.LX cells and is a subclone that stably expresses a
transgene (γ2b Igh gene) regulated by the 3′IghRR (Shi and Eckhardt 2001;
Henseler, Romer et al. 2009). Cells were grown in RPMI 1640 media
(MediaTech, Herndon, VA) supplemented with 10% bovine calf serum
(Hyclone, Logan, UT), 13.5 mM HEPES, 100 units/ml penicillin, 100 µg/ml
streptomycin, 2 mM L-glutamine, 0.1 mM nonessential amino acids, 1.0 mM
sodium pyruvate, and 50 µM β-mercaptoethanol. Cells were maintained at
37˚C in an atmosphere of 5% CO2. Cell viability was determined by assaying
1.0 mL of cell suspension for Trypan Blue exclusion staining with a ViCell
instrument (Beckman Coulter, Brea, CA).

Vertebrate Animals
To validate the results from the cell line studies, splenocytes from 6
week old female B6C3F1 mice were also utilized. No in vivo treatments were
performed and all animals were sacrificed by decapitation in accordance with
university policy and approved under the animal use protocol number 685
(AUP). After decapitation, the spleens were aseptically removed and placed
in sterile ice cold 1x PBS. The spleens were combined then homogenized
with frosted microscope slides, and the debris cleared by passing the
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homogenate through a screen filter. After filtration, the cells were centrifuged
for 5 min at 250 x g at 4◦C, the supernatant was discarded, and the cells were
washed with ice cold PBS with inversion. The cells were then subjected once
more to centrifugation for 5 min at 250 x g at 4◦C. The supernatant was again
discarded and the pellet was resuspended in 1 ml of red blood cell lysis buffer
(10 mM KHCO3, 150 mM NH4Cl, and 0.1 mM EDTA-pH 8.0) for 5 min, then
diluted 1:10 with ice cold PBS. The cells were subjected to a final
centrifugation for 5 min at 250 x g at 4◦C. The supernatant was discarded and
the pellet was resuspended in culture media. The cells were allowed to
incubate at 37◦C in an atmosphere of 5% CO2 for 2 hr. After the incubation,
the cells were slowly decanted out of the culture flask, counted with a ViCell
instrument (Beckman Coulter, Brea, CA), and resuspended in culture media
for use in chromatin immunoprecipitation (ChIP) assays.

Transient Transfection and Luciferase Assay
The Igh luciferase reporter plasmids were generously provided by Dr.
Robert Roeder (Rockefeller University, New York, NY). The VH-Luc-hs4 and
VH-Luc-3’IghRR plasmids consist of an upstream variable heavy chain (VH)
promoter, a luciferase gene and the hs4 enhancer or the 3’IghRR,
respectively, located downstream of the luciferase gene. Plasmids were
constructed using a pGL3 basic luciferase reporter construct (Promega,
Madison, WI) as described previously (Ong, Stevens et al. 1998). Transient
transfections were performed as previously described (Sulentic, Zhang et al.
2004; Henseler, Romer et al. 2009). Briefly, CH12.LX or CH12.IκBαAA cells
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(1.0x107) were resuspended in 200 µl of culture media with 10 µg of plasmid
(VH-Luc-hs4, or VH-Luc-3’IghRR) and transferred into a 2-mm gap
electroporation cuvette (Molecular BioProducts, San Diego, CA). Cells were
electroporated using an electro cell manipulator (ECM 630; BTX, San Diego,
CA) with the voltage at 250 V, the capacitance at 150 µF, and the resistance
at 75 ohms. For each plasmid, multiple transfections were combined together
in fresh media at 2.0x105 cells/ml then immediately treated with the following
treatment conditions and aliquoted in quadruplicate into a 12-well plate and
cultured for a 24 (VH-Luc-hs4) or 48-hr (VH-Luc-3’IghRR) incubation period in
5% CO2 at 37°C. For the CH12.LX cells, they were pretreated for 1 hr with
DMSO or 30 µM CH223191 (AhR antagonist, AhRA) then treated with DMSO
or 10 nM TCDD in the presence of 1 µg/ml LPS stimulation. The final DMSO
concentration was 0.11%. The CH12.IκBαAA cells were divided into two
equal portions and one portion was treated with 100 μM IPTG for 2 hr to
activate the IPTG-inducible IκBαAA transgene while the other portion was
cultured in the absence of IPTG to provide a control that lacked IκBαAA
transgene expression. An initial concentration response and time course was
conducted to determine the optimum concentration and time of addition for
IPTG-induced IκBαAA induction. After 2 hr of pretreatment with 100 µM
IPTG, the CH12.IκBαAA cells were treated with DMSO or varying
concentrations of TCDD (0.001-10 nM) with or without LPS stimulation
(0.001-1 µg/mL) then immediately aliquoted in quadruplicate into a 12-well
plate and cultured for 24 or 48 hr in 5% CO2 at 37°C. After a 24 (VH-Luc-hs4)
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or 48-hr (VH-Luc-3’IghRR) incubation period, cells were lysed with a 1x
reporter lysis buffer (Promega) and samples were immediately frozen at 80°C. To measure luciferase enzyme activity, samples were thawed at room
temperature and 20 µl of sample lysate was mixed with 100 µl of luciferase
assay reagent (Promega). Luciferase activity or luminescence was measured
with a luminometer (Berthold detection systems, Oak Ridge, TN) and
represented as relative light units or percent effect relative to the DMSO
control.

Protein Isolation for Western Blot Analysis
Following the appropriate treatment and incubation period,
CH12.IκBαAA cells were harvested using centrifugation (3000 rpm for 5 min
at 4◦C) and washed once with 1x PBS. The cells were resuspended in 150 µl
of mild lysis buffer (150 mM NaCl, 10 mM sodium phosphate pH 7.2, 2 mM
EDTA, and 1% Ipegal) and frozen at -80°C. For protein quantification, the
lysate was thawed on ice and resuspended briefly then centrifuged at 14,000
rpm for 5 min at 4◦C. The whole cell lysate was removed from the pelleted cell
debris, quantified by the Bio-Rad Protein Assay (Bio Rad, Hercules, CA)
according to manufacturer specifications, and frozen at -80°C until further
analysis.

Protein Isolation for Igγ2b Analysis
CH12.γ2b-3′IghRR cells, in the absence or presence of LPS (1 µg/ml),
R848 (1 µg/ml), or CpG (1 µM) stimulation, were treated with increasing
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concentrations of TCDD (0.003-30 nM) then plated into 12-well plates.
Treated CH12.γ2b-3′IghRR cells were plated at a concentration of 2.5x104
cells/well and incubated for 48 hr. Following the incubation period, cells were
centrifuged at 3000 rpm, lysed with mild lysis buffer containing freshly added
protease inhibitors (Complete Mini Protease Inhibitor Cocktail; Roche
Diagonostics, Indianapolis, IN). Lysed cells were centrifuged at 14,000 rpm
then supernatants were collected and stored at −80 °C until analysis. To
measure γ2b, cell lysates were thawed on ice and protein concentrations
were determined by a Bradford assay (Bio-Rad Laboratories, Hercules, CA).
Samples were then diluted to the lowest sample concentration and 2 µg of
total protein was analyzed for γ2b by ELISA.

Enzyme-Linked Immunosorbent Assay (ELISA)
Cell lysates were analyzed for γ2b by sandwich ELISA as described by
Henseler et. al.(Henseler, Romer et al. 2009). Briefly, colorimetric detection
was performed every minute over a 1 hr period using a Spectramax plus 384
automated microplate reader with a 405-nm filter (Molecular Devices,
Sunnyvale, CA). The SOFTmax PRO analysis software (Molecular Devices)
calculated the concentration of γ2b in each sample from a standard curve
generated from the kinetic rate of absorption for known γ2b concentrations.
Results are represented as percent effect relative to the stimulation with
DMSO control ± S.E. (n=3).

SDS-PAGE and Western Blot Analysis
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All whole cell lysates were thawed on ice and 50 µg of protein from
each extract were run on a 10% polyacrylamide gel at 200 volts for 30-40
minutes. The proteins were transferred from the gel to a polyvinylidene
fluoride (PVDF) membrane (Millipore, Bedford, MA) using an electric current
of 100 volts for 75 min. The membrane was then immediately immersed in
3% BSA (bovine serum albumin)/TTBS (tris-buffered saline with 0.05%
tween-20) and rocked overnight at 4°C. The membranes were incubated at
room temperature overnight in 3% BSA/TTBS with either a mouse anti-β-actin
(Sigma Aldrich) at a 1:10,000 dilution, rabbit anti-IκBα ([sc-371 (C-21), Santa
Cruz, Santa Cruz, CA]) at a 1:1000 dilution, or anti-AhR (ab2770 Abcam,
Cambridge, MA) at a 1:1000 dilution. The membrane was then washed four
times in TTBS at 10 minute intervals, and the blot was incubated with the
appropriate horse-radish-peroxidase (HRP)-conjugated secondary antibody
(goat anti-mouse at 1:8000 or goat anti-rabbit at 1:2500) for 1 hr. The blot
was washed again four times in TTBS, exposed to ECL substrate
(Thermoscientific, Waltham, MA) and analyzed on a Fuji LAS-3000 Bioimager
(Tokyo, Japan).

Chromatin Immunoprecipitation Assay (ChIP)
1.0 x 107/treatment condition CH12.LX cells or splenocytes were
treated with 1 µg/ml LPS, 0.0067% DMSO, and/or 30 nM TCDD and
incubated for 90 min at 37°C with 5% CO2. After incubation, cells were crosslinked with 1% formaldehyde for 10 min at room temperature with agitation.
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Glycine at a 125 mM final concentration was then added to each treatment
condition to quench the crosslinking and samples were agitated for an
additional 10 min. Samples were then centrifuge at 1800 x g for 5 min at 4°C.
The supernatant was discarded and the pellet resuspended in ice cold PBS
and centrifuge at 1800 x g for 5 min. at 4°C. The supernatant was again
discarded and the cells were subjected to ice cold lysis buffer-1 (50 mM
Hepes-KOH pH 7.5, 140 mM NaCl, 1 mM EDTA, 10% Glycerol, 0.5% Ipegal,
0.25% Triton X-100, and Protease Inhibitor Cocktail (PIC)) for 20 min on ice.
The samples were then centrifuge at 1800 x g for 5 min at 4°C. The
supernatant was discarded and the pellet resuspended in lysis buffer-2 (10
mM Tris-HCL pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, PIC) for 10
min at room temperature. The samples were then centrifuge at 1800 x g for 5
min at 4°C. The supernatant was discarded and the pellet resuspended in
350 µl ice cold low salt sonication buffer (40 mM Tris-HCL pH 8.0, 100 mM
NaCl, 1 mM EDTA, 1% Triton X-100, and PIC). Samples were sonicated with
a micro tip horn using a Sonicator (Heat Systems-Ultrasound, Inc. model W225) at 40% power for eight 20 sec constant pulses with resting for 20 sec on
an ice/water mix between pulses. After sonication, samples were
supplemented with 5 mM CaCl2, heated to 37°C, and treated with 120 units of
micrococcal nuclease (MNase) for 15 min at 37°C. EDTA and EGTA at 20
mM were added to the samples after heating to quench the MNase activity.
Additionally, the final concentration of NaCl was adjusted to 300 mM, and the
sample placed on ice for 10 min. Samples were then centrifuged at 20,000 x
41

g for 10 min at 4°C, and the supernatant transferred to 1.5 mL Eppendorf
tubes. The samples were then pre-cleared of proteins that non-specifically
bind the IP antibodies and of free antibody by mixing with 25 µl of protein Gcoated magnetic bead slurry and rotated at 4°C for 1 hr. The samples were
then cleared of the magnetic beads with a magnetic Eppendorf rack. Each
sample was then evaluated for total DNA by removing 10 µl of each sample,
extracting the DNA with phenol-chloroform extraction, and the DNA was
quantified with a NanoDrop Spectrophotometer (Thermo Scientific,
Wilmington, DE). All cleared Pre-IP samples were diluted to same amount of
DNA/sample within a treatment group and stored at -80°C until prepared for
use in the ChIP assay. The immunoprecipitation (IP) antibody [(anti-AhR
(ab2770 Abcam, Cambridge, MA), anti-RelA (A301-823A Bethyl Laboratories,
Inc., Montgomery, TX), or anti-RelB (A302-183A Bethyl Laboratories, Inc.,
Montgomery, TX))] was incubated at a concentration of 3 µg of antibody to
every 25 µl of protein G-coated magnetic bead slurry in 1.1 ml 1x NET buffer
(150 mM NaCl, 0.5 mM EDTA, 50 mM Tris-HCL, 0.5% Ipegal) for a minimum
of 4 hr at 4°C with rotation. After the first incubation, sheared salmon sperm
DNA was added to the IP/bead complex and rotated an additional 1 hr. The
magnetic beads were then cleared of excess/unbound antibody and salmon
sperm with a magnetic Eppendorf rack. The IP/bead complex was then
resuspended in 1xNET buffer and 25 µl added to each pre-cleared sample.
Samples were incubated overnight with rotation at 4°C. Samples were then
washed with a 150 mM NaCl wash, a 500 mM NaCl wash, a 250 mM LiCl
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wash, and finally a 10 mM TE wash. The samples (IP/bead complex with the
protein cross-linked to the DNA) were treated 2 times with 100 µl elution
buffer (100 mM NaHCO3, 1% SDS) for 15 min, and the eluent collected each
time. To reverse the cross-linking, the eluent was heated to 65°C and 195
mM NaCl was added to each sample in concert with 1 µl of RNase. The
samples were incubated for a minimum of 5 hr, cooled to 45°C and treated
with 1 µl Proteinase K for 2 hr. The DNA from the samples was extracted with
Phenol/Chloroform extraction, and the presence of DNA was validated with a
NanoDrop Spectrophotometer (Thermo Scientific, Wilmington, DE). The PCR
primers were: hs4 Forward Primer “CACACCCCACCTGTAGCAC”, hs4
Reverse Primer “TGAGGAGGTTGACATGATGG”, hs1,2 Forward Primer
“CTGATATCTGAGCCCCCAAC”, hs1,2 Reverse Primer
“GTGGTCTGGGTAATGGATGG”. β-actin primers were used to evaluate that
the initial DNA (pre-IP samples) was equally diluted so that changes in
threshold cycle (CT) could be attributed to treatment conditions within a
sample set. ChIP data is reported as % input (2-∆CT [normalized]), where ∆CT=
(CTChIP-(CTinput-log2 (Dilution Input Factor))) (Livak and Schmittgen 2001). The
Dilution Input Factor was 1/100. The data is reported as the combined
average from multiple experiments.

Statistical Analysis of Data
Mean ± S.E. was determined for each treatment group of a given
experiment. A statistical difference in the fold-effect between treatment
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groups and the controls was determined by 1-way ANOVA with a Dunnett’s
post-hoc test. Statistical differences in the fold-changes between the nonIκBαAA and IκBαAA-expressing cells were determined by either a two-tailed
t-test, a one-way ANOVA with a Dunnett’s post-hoc test or a two-way ANOVA
with a Bonferroni post-hoc test. Statistical difference between reporters was
determined by a two-way ANOVA with a Bonferroni post-hoc test. All
analyzed data is represented as the average for each treatment within each
experiment (each n), and combined for a minimum of n=3.
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CHAPTER 4. RESULTS

TCDD is a general Inhibitor of the 3’IghRR regardless of the Toll-like
receptor activated
Toll-like receptors (TLRs) play an important role in the first line of host
defense by recognition of microbial products. Mouse TLR4 is expressed on B
cells, macrophages, T cells, epithelial cells, monocytes, myeloid DCs and is
suspected to be present on many other cell populations (Iwasaki and Medzhitov
2004). Interestingly, human primary B cells have very low levels of TLR4 and
express large amounts of TLR9. In agreement with this dichotomy in TLR4 and
TLR9 expression in human B cells, LPS (TLR4 ligand) has a diminished ability to
activate human B cells (Guijarro-Munoz, Compte et al. 2014), while
hypomethylated CpG ODN (TLR9 ligand) strongly activates human B cells
(Bernasconi, Onai et al. 2003). In mice, TLR9 is expressed in plasmacytoid
dendritic cells (PDC), macrophage populations and B cells. In human
populations, TLR9 is expressed in B cells and PDCs (Poeck, Wagner et al.
2004). As with TLR4 or TLR9-induced B cell activation, both TLR7 and TLR8
have been shown to activate both human and murine B cells and are found in
dendritic cells (Iwasaki and Medzhitov 2004). Because of TLRs differences in
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expression and function between species, we wanted to investigate the effect
of TCDD on the activation of the 3’IghRR.
To evaluate if TCDD will inhibit the activation of the 3’IghRR regardless
of the TLR stimuli, we elected to use the CH12.γ2b-3′IghRR B cell line which
is a subclone isolated from CH12.LX cells that stably express a transgene
(γ2b Igh gene) regulated by the 3′IghRR (Shi and Eckhardt 2001; Henseler,
Romer et al. 2009). Briefly, upon 3′IghRR activation, the transgene in the
CH12.γ2b-3′IghRR B cells produces Igγ2b that can be evaluated with an
ELISA assay. CH12.γ2b-3′IghRR B cells were treated with either; R848 (1
µg/ml), CpG (1 µM), DMSO (0.019 to 0.119%) and/or with increasing
concentrations of TCDD (0.003-30 nM) (Figure 7). An LPS (1 µg/ml) control
was used with either DMSO (0.119%) or a TCDD (30 µM) co-treatment for a
secondary control to validate the TCDD induced inhibition of the 3’IghRR.
Treatment with R848 activated the 3’IghRR, while the addition of increasing
concentrations of TCDD demonstrated a concentration dependent inhibition
of the 3’IghRR reporter (Figure 7A). As with R848 treatment, CpG induced
activation of the B-cells was reversed by a co-treatment with TCDD leading to
significant inhibition of the CpG induced activation of the 3’IghRR (Figure 7B).
As all three stimuli activate the 3’IghRR likely through the NF-κB/Rel signaling
pathway, we elected to further investigate the role that NF-κB/Rel proteins
play in the effects of TCDD inhibition on the 3’IghRR by using LPS as our
activation stimuli and the CH12.IκBαAA B cell line.
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Figure 7. TCDD is a general inhibitor of TLR activation of the 3’IghRR
CH12.γ2b-3′IghRR B cells were treated with either; R848 (1µg/ml) (A) or CpG
(1µM) (B) and co-treated with increasing concentrations of TCDD (nM). LPS
(1 µg/ml) and TCDD (30 nM) co-treatment (positive control) was normalized
to an LPS co-treated with DMSO that was set to 100 percent. ** p<0.01,
***p<0.001 via one-way ANOVA with a Dunnett’s post hoc test when
compared to the appropriate 0.0 (DMSO plus stimulation) control, n=3.
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Characterization of the CH12.IκBαAA B cell line
To initiate studies that directly evaluate the role of NF-κB/Rel proteins
in the effects of LPS and TCDD on 3’IghRR activity, we chose to utilize a
variant of the CH12.LX mouse B cell line, the CH12.IκBαAA B cell line. The
CH12.LX B-cell line model has been extensively utilized in studying the
effects of TCDD on B cell function and Ig expression (Sulentic, Holsapple et
al. 1998; Sulentic, Holsapple et al. 2000; Sulentic, Kang et al. 2004; Sulentic,
Zhang et al. 2004). The CH12.IκBαAA cell line stably expresses an IPTGinducible IκBα super repressor protein (IκBαAA) which is resistant to negative
feedback regulation by NF-κB/Rel proteins (Hsing and Bishop 1999; Romer
and Sulentic 2011). NF-κB activation occurs when a stimulus activates an
inhibitory κB kinase (IKK) which targets an inhibitory IκBα protein for
proteolytic degradation. The degradation of IκBα allows the NF-κB/Rel
transcription factors (e.g. RelA and to lesser extent c-Rel) to translocate to the
nucleus and facilitate transcription (Figure 5) (Sen and Baltimore 1986;
Baeuerle and Baltimore 1988). As the AhR and NF-κB/Rel proteins have
been shown to associate ((Tian, Ke et al. 1999; Vogel, Sciullo et al. 2007) and
TCDD’s effects are believed to mediated through the AhR, the CH12.IκBαAA
cell line was selected as an appropriate cell line to investigate the role of NFκB/Rel on the effect of TCDD-induced inhibition of the 3’IghRR.

48

Inducible expression of the IκBαAA
To evaluate the appropriate concentration of IPTG required to induce
expression of the IκBαAA, we treated the CH12.IκBαAA B cells with 1 to 400
µM IPTG overnight followed by whole cell protein isolation and western blot
analysis. An anti-IκBα antibody identified both the endogenous IκBαAA
protein (approximately 37-kDa) and the slightly larger IκBαAA. Pretreatment
with IPTG demonstrated a concentration-dependent increase in IκBαAA
expression with concentrations of IPTG greater than 10 µM (Figure 8A). The
maximal expression of the IκBαAA was induced by 100 µM IPTG, which was
chosen as our working concentration.
Minimal pretreatment time induce expression of the IκBαAA
Transient transfections utilized in this investigation required 24 hr (hs4
enhancer) to 48 hr (3’IghRR) incubation periods post transfection. 24 hr of
IPTG pretreatment after transfection, combined with the additional treatment
times resulted in a decrease in cell number and inhibited cell proliferation
(data not shown). To evaluate the minimum amount of time necessary to
induce IκBαAA expression, CH12.IκBαAA cells were treated with 100 µM
IPTG and whole cell lysates were isolated hourly for 5 hr. Western blot
analysis demonstrated a time-dependent increase in IκBαAA expression
which was maximal by 2 hr of IPTG treatment (Figure 8B). Therefore,
subsequent studies utilized a 2 hr pretreatment with 100 µM IPTG to induce
IκBαAA expression.
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Figure 8. Inducible expression of the IκBαAA super-repressor
(A) CH12.IκBαAA B cells were treated with 1 to 400 µM IPTG overnight
followed by whole cell protein isolation and western blot analysis. An antiIκBα antibody identified both the endogenous IκBαAA protein (approximately
37-kDa) and the slightly larger IκBαAA. (B) CH12.IκBαAA cells were treated
with 100 µM IPTG and whole cell lysates were isolated hourly for 5 hr.
Western blot analysis demonstrated a time-dependent increase in IκBαAA
expression which was maximal by 2 hr of IPTG treatment.
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AhR expression and function in the CH12.IκBαAA cells
A functioning AhR signaling pathway is an important characteristic of a
suitable model to study the effects of TCDD on Igh transcriptional regulation.
Therefore AhR expression and function were evaluated in the CH12.IκBαAA
cells and compared to the parental and well-characterized CH12.LX B cell
line. AhR protein levels were analyzed by western blot analysis and
demonstrated much lower basal levels in CH12.IκBαAA cells compared to the
CH12.LX cells (Figure 9). However, LPS stimulation at 1 µg/ml for 12 hr
induced AhR protein levels in both cell lines (Figure 9) as previously seen in
the CH12.LX cells (Marcus, Holsapple et al. 1998) and in primary B cells
(Marcus, Holsapple et al. 1998; Tanaka, Kanaji et al. 2005). Additionally,
treatment with 10 nM TCDD for 12 hr decreased AhR levels in both cell lines
in agreement with studies by Pollenz et. al. (Pollenz 1996). IκBαAA
expression had no effect on basal AhR expression or the expression profile
induced by LPS or TCDD (Figure 9B). Moreover, as a measure of AhR
function, TCDD induced Cyp1a1 mRNA expression, quantified by RT-PCR
analysis, in the CH12.IκBαAA cells (Figure 10). However, the level of Cyp1a1
induction by TCDD was significantly less in CH12.IκBαAA as compared to
CH12.LX, which was consistent with the lower basal levels of AhR in the
CH12.IκBαAA B-cell line. Taken together, these results suggest that although
the basal and induced AhR levels are much lower in CH12.IκBαAA cells
compared to CH12.LX cells, there are similar effects on AhR expression and
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function that support the use of the CH12.IκBαAA cells as a model for
evaluating the effects of TCDD and AhR activation on NF-κB-induced
modulation of the Igh.
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Figure 9. AhR expression and function in the CH12.IκBαAA B cells
CH12.LX (LX) and CH12.IκBαAA (-,+ IPTG) B cells were treated with 100 µM
IPTG, 1µg/ml LPS, and/or 10 nM TCDD. Whole cell lysates were collected
after 1 hr (A) or 12 hr (B) and 50 µg whole cell lysate was loaded for each
sample. The western blot was probed with either an anti-AhR antibody or an
anti-β-actin antibody (loading control).
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Figure 10. Cyp1A1 expression in the CH12.LX and CH12.IκBαAA cells.
Total RNA was isolated from naïve (NA) cells, or cells treated with vehicle
(0.019% DMSO), or TCDD (30 nm) for 24 hr. The RNS was reversed
transcribed (1µg) to cDNA, then analyzed (5ng) by SYBR Green Real-time
PCR. The fold change compared to CH12.LX is represented as a relative
quantification (RQ) value is relative to CH12.LX-NA (experiments conducted
and analyzed by Dr. Courtney Sulentic. Ph.D.). n=2
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IκBαAA expression abrogates the inhibitory effect of TCDD on 3′IghRR
activation and the synergistic activation of hs4
Within the 3’IghRR lie four discreet enhancers; the hs1,2, hs3a, hs3b,
and the hs4. As demonstrated by Fernando et. al., 2012, the murine hs1,2
activation state mirrors the activation states of the 3’IghRR when activated
with LPS and co-treated with TCDD (Fernando, Ochs et al. 2012). However,
the dichotomy between the inhibitory effect of TCDD on 3’IghRR activation
and the synergistic activation of the hs4 enhancer as described by Sulentic et.
al., 2004 is prevalent in our current results with the exception of a modest
decrease in sensitivity to TCDD-induced inhibition of the 3’IghRR (Sulentic,
Zhang et al. 2004). The shift in sensitivity to TCDD is likely due to the lower
levels of AhR expressed in CH12.IκBαAA as compared to CH12.LX cells.
Interestingly, within the hs4 enhancer, the AhR and NF-κB/Rel proteins are
shown to converge at an overlapping dioxin responsive element (DRE) and
κB motif to influence synergistic transcriptional activity of the hs4 enhancer
(derived through mutational analysis) (Sulentic, Kang et al. 2004). These data
suggest that NF-κBs may play a significant role in concert with TCDD-induced
AhR activation to synergistically activate the hs4. Equally important, are the
DRE-like and κB identified motifs within the hs1,2 enhancer that may
contribute to the overall inhibition of the 3’IghRR. Therefore, to determine if
the NF-κB/Rel proteins inhibited by IκBα (mostly RelA and to a lesser extent
c-Rel) play a role in 3’IghRR activation by LPS or inhibition by TCDD,
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CH12.IκBαAA B cells were transiently transfected with a luciferase reporter
regulated by the VH promoter and either the 3’IghRR (Figure 11) or the hs4
enhancer reporter plasmid (Figure 12). Transfected cells for each plasmid
were immediately combined, split into equally into two volumes, and one
volume was pre-treated with 100 µM IPTG. Following a 2 hr incubation
period, transfected cells were treated with varying concentrations of LPS or
TCDD in the absence or presence of IκBαAA expression.
When the CH12.IκBαAA cells were not treated with IPTG, increasing
concentrations of LPS increased the activation state of the 3’IghRR.
Interestingly, addition of 10 nM TCDD at each increasing concentration of
LPS treatment significantly reversed the LPS-induced activation of the
3’IghRR greater than at the previous LPS treatment concentration (Figure
11A). Induction of the IκBαAA with IPTG lowered the overall LPS-induced
3’IghRR activation, but more importantly reversed the TCDD-induced
inhibition of the 3’IghRR (Figure 11 A). Additionally, when the CH12.IκBαAA
cells were not treated with IPTG, but treated with 1 µg/ml of LPS and
increasing concentrations of TCDD (0.01-10 nM), the LPS-induced activation
of the 3’IghRR was inhibited by TCDD in a concentration-dependent manner
(Figure 11C and D). However, with the induction of IκBαAA, the overall
activation of the 3’IghRR was blunted, but more importantly, the TCDDinduced inhibition of the 3’IghRR was reversed (Figure 11C and D). These
data suggest that the IκBα-regulated NF-κB/Rel proteins play a role in the
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both the LPS-induced activation, and the TCDD-dependent inhibition of the
3’IghRR.
The hs4 enhancer within the 3’IghRR has overlapping binding sites for
the AhR and NF-κB/Rel proteins and has been shown to synergistically
activate in response to a combined treatment of LPS and TCDD (Sulentic,
Kang et al. 2004) suggesting a cooperative interaction between AhR and NFκB/Rel proteins. When the CH12.ΙκBαAA cells were not treated with IPTG;
increasing concentrations of LPS (0.01-1 µl) marginally activated the hs4
enhancer, addition of 10 nM TCDD at each increasing concentration of LPS
treatment more greatly synergistically activated the TCDD-induced activation
of the hs4 enhancer greater than at the previous LPS treatment concentration
(Figure 12A and B). Induction of the IκBαAA with IPTG blunted the overall
LPS induced hs4 activation, but significantly inhibited and plateaued the
TCDD-induced synergistic activation of the hs4 at each LPS concentration
(Figure 12A and B). Additionally, when the CH12.IκBαAA cells were not
treated with IPTG, but treated with 1 µg/ml of LPS and increasing
concentrations of TCDD (0.01-10 nM), the TCDD-induced activation of the
hs4 enhancer was synergistically activated by TCDD in a concentrationdependent manner (Figure 12C and D). However, with the induction of
IκBαAA, the overall LPS induced activation of the hs4 was blunted, but more
importantly, the TCDD-induced activation of the hs4 was significantly inhibited
(Figure 12C and D). Consistent with previous mutational analysis studies in
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the CH12.LX B-cell line (Sulentic, Kang et al. 2004) and with the data
generated from the above studies with the 3’IghRR, these data suggest that
the IκBα-regulated NF-κB/Rel proteins play a role in the LPS and TCDDinduced synergistic activation of the hs4 enhancer.
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Figure 11. IκBαAA expression abrogates the inhibitory effect of TCDD
on 3′IghRR activation
CH12.IκBαAA cells were cultured in the presence or absence of 100 µM
IPTG for 2 hr after being transiently transfected with the 3′IghRR luciferase
reporter. Cells were then either (A,B) stimulated with increasing
concentrations of LPS (µg/mL) and co-treated with vehicle control (0.01%
DMSO) or TCDD (10 nM) for 48 hr or (C,D) LPS (1 µg/mL) and co-treated
with vehicle control (0.01% DMSO) or 0.01 to 10 nM TCDD for 48 hr (C, D).
The percent effect relative to the appropriate DMSO control (set to 100%) for
the data in A and B is represented in C and D respectively. * , **, or *** denote
significance at p<0.05, p<0.01, and p<0.001 respectively, derived from a oneway ANOVA with a Dunnett’s post hoc test used within a treatment group
compared against the respective DMSO control. A two-way ANOVA with a
Bonferroni post hoc test was utilized to determine significance, from the
appropriate DMSO control. ‡ denotes significance between the Control group
(no induced IκBαAA) and IκBαAA test group at p<0.05, (A, C). A two-way
ANOVA Bonferroni post hoc test was utilized to determine significance, from
the appropriate DMSO control via. *, ** denotes significance between the
Control group (no induced IκBαAA) and IκBαAA test group at p<0.05, p<0.01
(B,D).
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Figure 12. IκBαAA expression inhibits the synergistic activation of hs4
CH12.IκBαAA cells were cultured in the presence or absence of 100 µM
IPTG for 2 hr after being transiently transfected with the hs4 luciferase
reporter. Cells were then either (A,B) stimulated with increasing
concentrations of LPS (µg/mL) and co-treated with vehicle control (0.01%
DMSO) or TCDD (10 nM) for 48 hr or (C,D) LPS (1 µg/mL) and co-treated
with vehicle control (0.01% DMSO) or 0.01 to 10 nM TCDD for 48 hr (C, D).
The percent effect relative to the appropriate DMSO control (set to 100%) for
the data in A and B is represented in C and D respectively. *, ** denote
significance at p<0.05 and p<0.01 respectively, derived from a one-way
ANOVA with a Dunnett’s post hoc test used within a treatment group
compared against the respective DMSO control. A two-way ANOVA with a
Bonferroni post hoc test was utilized to determine significance, from the
appropriate DMSO control. ‡ denotes significance between the Control group
(no induced IκBαAA) and IκBαAA test group at p<0.05, (A and C). A two-way
ANOVA Bonferroni post hoc test was utilized to determine significance, from
the appropriate DMSO control via. *, ** denotes significance between the
Control group (no induced IκBαAA) and IκBαAA test group at p<0.05, p<0.01
(B,D).
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CH223191 abrogates the inhibitory effect of TCDD on 3’IghRR
activation and the synergistic activation of hs4
The suppressive effect of TCDD on the immune system has long been
speculated to be mediated through the activation of the AhR signaling
pathway. We elected to inhibit the AhR signaling pathway with the AhR
antagonist, CH223191, to investigate the role the AhR on 3’IghRR inhibition
and hs4 activation. Addition of the (30 µM) antagonist pretreatment when
combined with LPS and TCDD fully reversed the inhibitory effect of TCDD on
the 3’IghRR (Figure 13), suggesting that the AhR is a primary target of TCDDinduced suppression. Contrary to the complete reversal of the 3’IghRR
inhibition, the hs4 synergistic activation was only partially, but still significantly
reduced, with the addition of the AhR antagonist (Figure 13).
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Figure 13. CH223191 reverses the effect on the 3’IghRR and the hs4
The CH12.LX B cells were transiently transfected with either the 3’IghRR
plasmid, or the hs4 plasmid and treated with 1µg/ml LPS, 10 nM TCDD (T),
0.02% DMSO, and /or 30 µM CH223191(Antagonist [A]). Treatment of the
CH12.LX B cells with CH223191 completely reversed the inhibitory effects of
TCDD on the 3’IghRR (A). Treatment of the CH12.LX B cells will CH223191
significantly inhibited the TCDD and LPS induced synergistic activation of the
hs4 enhancer. ***=p<0.001 via a one-way ANOVA with a Dunnett’s post hoc
test when compared to the respective control. ‡=p<0.01 via a two-way
ANOVA with a Bonferroni post hoc test when compared to the respective
TCDD treatment without the CH223191 treatment, n=3.
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NF-κB/Rel contributes to the TCDD induced inhibition of the 3’IghRR
As the data generated from inducing the IκBαAA supported a
functional role of the NF-κB’s to further increase TCDD’s inhibition of the
3’IghRR and increase the synergistic activation of the hs4, ChIP analysis was
performed to investigate alterations of NF-κB and AhR binding profiles within
two enhancer regions within the 3’IghRR (hs1,2 and hs4) in response
treatment to TCDD. Either the CH12.LX B-cell line or the homogenate from
murine spleens of female B6C3F1 mice (a strain that expresses a high affinity
AhR and has a functional AhR signaling pathway) were treated with LPS,
DMSO, and/or TCDD for 90-120min. The CH12.LX cell line model was
chosen secondary to the high basal level of constitutively expressed AhR,
thus maximizing the probability of elucidating LPS/TCDD induced alterations
in protein to DNA binding profiles. After crosslinking, sonication, and MNase
DNA cleavage, the lysates were subjected to immunoprecipitation (IP) with
anti-RelA, anti-RelB, or anti-AhR as the IP antibody. The results demonstrate
that within the hs1,2 and the hs4 (both in the CH12.LX B-cell line and in the
murine spleen homogenate): NF-κB/RelA (Figure 14) binding is increased in
response to TCDD treatment, and NF-κB/RelA binding is further increased
when LPS is added to the TCDD treatment; NF-κB/RelB (Figure 15) binding
increases in response to TCDD treatment, but interestingly, the binding of NFκB/RelB is markedly decreased in response to treatment of both LPS and
TCDD; AhR (Figure 16) binding is increased in the spleen homogenate in
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response to TCDD treatment, and in all samples AhR binding was markedly
increased in the presence of LPS and TCDD.
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Figure 14. NF-κB/RelA binding is increased within the 3’IghRR in
response to TCDD treatments
Ch12.LX B cells (A, B) or the homogenate from murine spleens (C, D) were
treated with LPS (1µg/ml), DMSO (0.01%), and or TCDD (30 nM). After 90120 min of treatment, the samples were cross-linked with Formaldehyde, and
prepared for ChIP analysis. The samples were subjected to an IP with an
anti-NF-κB/RelA antibody. PCR analysis of the samples demonstrate that
CH12.LX B cells and spleen homogenate when treated with either TCDD or
LPS and TCDD combined significantly induced NF-κB/RelA to associate with
the hs1,2 enhancer (A, C) and the hs4 enhancer (B, D). *=p<0.05, **=p<0.01,
***=p<0.001 via a one-way ANOVA with a Dunnett’s post hoc test when
compared to the respective control (TCDD compared to DMSO treatment, or
LPS and TCDD compared to LPS and DMSO control).
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Figure 15. NF-κB/RelB binding is increased within the 3’IghRR in
response to TCDD treatments but inhibited by an LPS and TCDD cotreatment
Ch12.LX B cells (A, B) or the homogenate from murine spleens (C, D) were
treated with LPS (1µg/ml), DMSO (0.01%), and or TCDD (30 nM). After 90120 min of treatment, the samples were cross-linked with Formaldehyde, and
prepared for ChIP analysis. The samples were subjected to an IP with an
anti-NF-κB/RelB antibody. PCR analysis of the samples demonstrate that
CH12.LX B cells when treated with TCDD significantly induced NF-κB/RelB to
associate with the hs1,2 enhancer (A) and the hs4 enhancer (B). TCDD
treatment of the spleen homogenate demonstrated a trend of increased
association of NF-κB/RelB to both the hs1,2 (C) and the hs4 enhancer (D).
When either the CH12.LX B cells or the spleen homogenate was subjected to
a combined treatment of TCDD and LPS, the association of NF-κB/RelB was
significantly reduced in both the hs1,2 enhancer (A, C) and the hs4 enhancer
(B, D). *=p<0.05, **=p<0.01 via a one-way ANOVA with a Dunnett’s post hoc
test when compared to the respective control (TCDD compared to DMSO
treatment, or LPS and TCDD compared to LPS and DMSO control).
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Figure 16. AhR binding is increased within the 3’IghRR in response to
TCDD treatments
Ch12.LX B cells (A, B) or the homogenate from murine spleens (C, D) were
treated with LPS (1µg/ml), DMSO (0.01%), and or TCDD (30 nM). After 90120 min of treatment, the samples were cross-linked with Formaldehyde, and
prepared for ChIP analysis. The samples were subjected to an IP with an
anti-AhR antibody. PCR analysis of the samples demonstrate that TCDD
treatment of CH12.LX B cells did not alter the association of AhR within the
hs1,2 enhancer (A) or the hs4 enhancer (B). However, TCDD treatment of the
spleen homogenate demonstrated a significant increased association of AhR
to both the hs1,2 (C) and the hs4 enhancer (D). When either the CH12.LX B
cells or the spleen homogenate was subjected to a combined treatment of
TCDD and LPS, the association of AhR was significantly increased in both
the hs1,2 enhancer (A, C) and the hs4 enhancer (B, D). *=p<0.05, **=p<0.01,
***=p<0.001 via a one-way ANOVA with a Dunnett’s post hoc test when
compared to the respective control (TCDD compared to DMSO treatment, or
LPS and TCDD compared to LPS and DMSO control).
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CHAPTER 5. DISSCUSSION

The combustion of organic material in the presence of chlorine produces
halogenated aromatic hydrocarbons (HAH). Chlorine is found as a primary
constituent in plastics, textiles, solvents, agrochemicals, insecticides, and in a
myriad of common use substances. TCDD is the most potent of the
environmentally persistent halogenated aromatic hydrocarbons, and has been
the greatest HAH investigated secondary to high profile contaminations involving
both humans and wildlife (White and Birnbaum 2009). Although there are
significant differences in both intra-species and inter-species sensitivity to TCDD,
exposure to TCDD in sensitive models is correlated to a plethora of disease
states. The focus of our current study was to investigate the mechanism by which
TCDD alters the activations states of the 3’IghRR.
Consistent with studies using T-cell independent activation of B cells
through the use of LPS, CpG, or R848, our results demonstrated a TCDD cotreatment dependent inhibition of 3’IghRR activation. The inhibition of the
3’IghRR activation mirrored a TCDD co-treatment dependent reduction of the
production of IgM in response to activation through the Toll-like receptors by
LPS, CpG, and R848 (North, Crawford et al. 2010). The authors of the study
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demonstrated alterations in the phosphorylated states of signal transduction
proteins upstream of the transcription factors, NF-κB/Rel and AP-1, in response
to TCDD co-treatments with the TLR agonists. Multiple transcription binding sites
have been identified within the 3’IghRR including sites for NF-κB/Rel, Pax5, Oct,
and AP-1 (as reviewed by (Sulentic and Kaminski 2011)).
To initially investigate the role that NF-κB/Rel proteins played in the
modulation of TCDD dependent inhibition of the 3’IghRR, we elected to use the
well characterized CH12.IκBαAA cell line that stably expresses an IPTGinducible IκBα super repressor protein (IκBαAA). The induced IκBαAA is
resistant to negative feedback regulation by NF-κB/Rel proteins (Hsing and
Bishop 1999). The use of CH12.IκBαAA cell line provided a tool to selectively
liberate or retarded the transcriptional active form of NF-κB/Rel proteins in
response to a treatment with LPS. Although the CH12.IκBαAA cell line
demonstrated a markedly lower level of constitutively expressed AhR, the cell
line was sensitive to treatments with TCDD, and mirrored previous results by
Sulentic et al., using the parental CH12.LX cell line (Sulentic, Zhang et al. 2004).
However, the degree of inhibition of the 3’IghRR in the CH12.IκBαAA cell line in
response to a LPS and TCDD co-treatment was modestly less when compared
to the parental CH12.LX cell line (data not shown). These results support the
theory that TCDD toxicity is not only dependent on the AhR, but equally
important, low levels of constitutively expressed AhR can have a significant
impact on toxicity in dioxin sensitive models. Interestingly, the results from the
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expression of the IκBαAA in the CH12.IκBαAA cell line suggested that both the
AhR as well as NF-κB/Rel play a functional role in overall inhibition of the
3”IgHRR in response to a co-treatment with TCDD. In the absence of TCDD,
LPS significantly enhances the activation state of the 3’IghRR, and has little
effect on the activation of the hs4. However, the addition of TCDD in concert with
LPS markedly inhibits the 3’IghRR activation and synergistically activates the
hs4. Interestingly, when a co-treatment involved increasing the concentration of
LPS or TCDD, the percent of 3’IghRR inhibition or the synergistic activation of
the hs4 was significantly increased. These results suggest that both the AhR and
intra cellular proteins released in response to TLR activation are functioning
together to enhance the suppressive effect of TCDD. Moreover, the expression
of IκBαAA significantly altered the effect that TCDD combined with LPS had on
both the 3’IghRR and the hs4. Increasing the concentration of either LPS or
TCDD had significantly less of an effect on the suppression of 3’IghRR or the
synergistic activation of the hs4. Taken together, these results further suggest
that the proteins that are regulated by the IκBα (NF-κB/RelA and to a lesser
extent NF-κB/c-Rel) have a contributing role in the suppression of the TCDD
induced inhibition of the 3’IghRR and the synergistic activation of the hs4. The
activation of NF-κB/RelA by LPS significantly enhances the activation state of the
3’IghRR. Conversely LPS-induced NF-κB/RelA activation significantly enhances
the inhibition of the 3’IghRR when B-cells are activated by LPS in the presence of
TCDD. Furthermore, we were able to demonstrate a full reversal of the TCDD
dependent inhibition of the LPS induced activation of the 3’IghRR with the AhR
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antagonist CH223191, and a partial, yet significant reversal of the synergistic
activation of hs4. These data further demonstrates that the effect of B cell
immune suppression by dioxin is dependent on a functional and sensitive AhR.
These results suggest that NF-κB/RelA and AhR pathways converge within the
3’IghRR and cooperatively mediate TCDD suppressive effect on TLR-induced B
cell activation.
The entire 3’IghRR is necessary for LPS induced Ig transcription and CSR
in all B cells (Vincent-Fabert, Fiancette et al.). Additionally, the 3’IghRR is
associated with multiple disease states such as: dermatitis herpetiformis, plaque
psoriasis, psoriatic arthritis, IgA renal nephropathy, coeliac disease, systemic
sclerosis, and Burkitt's lymphoma (Madisen and Groudine 1994; Aupetit, Drouet
et al. 2000; Frezza, Giambra et al. 2004; Frezza, Giambra et al. 2007; Cianci,
Cammarota et al. 2008). Furthermore, the 3’IghRR has been implicated in
dysregulation of the oncogene, c-myc, via chromosomal translocation. The
dysregulation of c-myc is highly correlated with mature B-cell neoplasms
(Vincent-Fabert, Fiancette et al. 2010). Interestingly, and consistent with 3’IghRR
dysregulation, NF-κB dysregulation and activation has been implicated in: plaque
psoriasis, psoriatic arthritis, IgA renal nephropathy, coeliac disease, and Burkitt's
lymphoma (Knecht, Berger et al. 2001; Ashizawa, Miyazaki et al. 2003; Bell,
Degitz et al. 2003; Maiuri, De Stefano et al. 2003; Abdou and Hanout 2008;
Lories, Derese et al. 2008; Trynka, Zhernakova et al. 2009). Review of the
current literature demonstrated conflicting emphasis for the role of the hs4
enhancer. The hs4 enhancer has been shown to be an essential and necessary
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enhancer in class switch recombination (CSR) and Ig transcription in plasma
cells, provided it is paired with hs3b (Manis, van der Stoep et al. 1998; Pinaud,
Khamlichi et al. 2001; Vincent-Fabert, Truffinet et al. 2009). However, Collins et
al. demonstrated that hs4 plays a significant role in CSR for the Ig isotype of Igγ3
and Igγ2b in transgenic C57BL/6 mice splenic B cells (Dunnick, Shi et al. 2011).
Alterations of the physiological “normal” state of the 3’IghRR (including alteration
of activation states of the 3’IghRR’s hs enhancers) may lead to the exacerbation
of disease pathology and a lowered ability to effectively respond to an
immunologic insult.
Many studies have demonstrated an association between the AhR and
NF-κB/Rel proteins ((Tian, Ke et al. 1999; Kim, Gazourian et al. 2000; Jensen,
Leeman et al. 2003; Vorderstrasse, Dearstyne et al. 2003; Vogel, Sciullo et al.
2007). However, the AhR and NF-κB/Rel associations were cell-type specific,
dependent upon the measured outcome, and either enhanced transcription or
suppressed transcription of the selected gene targets. Consistent with the results
demonstrated by those studies, our lab was also able to identify an association
between the AhR and the NF-κB proteins, RelA (p65) and RelB (p68), in the
CH12.LX murine B-cell line (data not shown), however, we were unable to
consistently establish a treatment dependent association. Interestingly, we were
able to demonstrate an NF-κB/RelA and NF-κB/RelB association with AhR if the
AhR was immonoprecipitated (Ip’d), but we were unable to visualize the AhR
association with NF-κB/Rel if we Ip’d NF-κB/Rel. Both Vogel, and Tian, have
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published excellent reviews that explore the potential functional roles that involve
the AhR/NF-κB interaction and how those unique interactions may play a vital
role in intracellular processes (Vogel, Sciullo et al. 2007; Tian 2009).
Interestingly, Sulentic et. al., demonstrated that within the hs4 enhancer, and in
the presence of a functional AhR pathway, treatment with TCDD alone
preferentially induced binding of NF-κB/RelA over the binding of RelB. However,
in the absence of a functional AhR, TCDD induced preferential and significant
binding of NF-κB RelB over RelA to the hs4 enhancer (Sulentic, Holsapple et al.
2000). Taken together, these results would support that not only does an AhR
dependent shift in the binding profile of transcription factors modulate the activity
of the unique enhancers within the 3’IghRR, but an LPS-induced NF-κB
dependent shift in binding profiles is altered by the activation of the AhR with
TCDD. The results from the ChIP data support that upon LPS activation, the
presence of TCDD leads to a further increase in NF-κB/RelA binding to both the
hs4 and hs1,2 enhancer. In addition to the increase in NF-κB/RelA binding, NFκB/RelB binding is markedly decreased in response to the addition of LPS
combined with a treatment of TCDD suggesting that the alterations in NFκB/RelA binding are a prime candidate that contributes to the overall inhibition in
the murine 3’IghRR induced transcription of the Igh. That said, we cannot rule out
that the epitope on the NF-κB/RelB may have been mask by an interaction of
NF-κB/RelB and the AhR. The masking of the epitope could have rendered our
anti-RelB antibody ineffective in the ChIP assay. Furthermore, The ChIP
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experiments were conducted at early treatment times (cells were subjected to
crosslinking after approximately 90 min of treatment). Bode et. al., investigated
the kinetics of RelA activation in response to LPS and CpG treatment in dendritic
cells (Bode, Schmitz et al. 2009). The data demonstrated that IκBα (RelA
activation) was rapidly degraded (within 5-10 min) in response to LPS activation,
whereas IκBβ (RelB activation) failed to show degradation within the first 2 hr of
LPS treatment. It is highly possible that the fast LPS-induced degradation of the
IκBα allowed for NF-κB/RelA to “out-compete” NF-κB/RelB for κB binding within
the enhancers. Additionally, as AhR has been shown to inhibit the activation
state of the 3’IghRR, activation of the AhR by TCDD is a powerful tool to
elucidate the underlying mechanisms by which the 3’IghRR is inhibited. The
overall inhibition of the 3’IghRR may prove to have a therapeutic benefit in the
aforementioned disease states. Furthermore, the convergence of these two
transcriptional pathways may prove to be a therapeutic target to enhance
suppression of the 3’IghRR.
In conflict to the present study, Fernando et al., demonstrated that there
are species dependent variations within the 3’IghRR that may contribute to
altered and conflicting sensitivities to TCDD. Fernando et al., demonstrated that
the LPS induced activation of the: mouse hs1,2 (ms-hs1,2), the 3’IghRR, and the
endogenous transcription of the Ig Heavy chain were all significantly inhibited by
a co-treatment with TCDD when examined in a mouse derived cell line. However,
when the human (hu-hs1,2) enhancer was transfected into either CH12.LX cell
line or a human IM9 B cell line, the hu-hs1,2 was significantly activated in
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response to LPS and TCDD (Fernando, Ochs et al. 2012). The authors of the
study speculated that of the many possibilities as to why the hu-hs1,2 enhancer
functioned in a manner inconsistent with the ms-hs1,2, was secondary to the lack
of a high-affinity Pax5 binding site within the ms-hs1,2. Interestingly, Lu et al.
demonstrated that 75% of human donor primary B cells samples that were tested
demonstrated a significant reduction in Ig expression in response to a treatment
with TCDD. In the same study, 16.6% of the samples were insensitive to TCDD,
and 8% of the samples showed an increase in Ig expression in response to
TCDD treatment (Lu, Crawford et al. 2010). Taken together, these data suggest
that; the well-known alterations in the structure of the AhR (altering the sensitivity
of the AhR to an agonist), alterations in the non-conserved sequences within the
3’IghRR (both between intra and interspecies), a symptomatic disease state (i.e.
autoimmune) in a tested subject, the concentration of an AhR agonist, and the
degree to which the immune system is activated by an antigen can impact the
outcome of an immune response to an AhR agonist. It would be of great scientific
interest to transiently transfect a hu-3’IgHRR into both the CH12.LX and IM9 B
cell line to further elucidate alterations in sensitivity to TCDD, as there is much
work yet to be done.
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CHAPTER 6. CONCLUSION

There is still much work that needs be accomplished to elucidate the
mechanisms by which TCDD dysregulates the immune system. Although, we are
gaining a stronger understanding of the roles that NF-κB/Rel and AhR contribute
to alterations in transcription of sensitive genes, transgenic mice may prove to be
a beneficial model. Collins, et. al. has developed a C57BL/6 transgenic mice that
contains either the complete 3’IghRR, or multiple variations of the 3’IghRR hs
enhancer regions (Dunnick, Shi et al. 2011). The C57BL/6 mouse model has
historically been sensitive to dioxin. Splenocytes harvested from the transgenic
model would allow for the investigation of the impact of dioxin on each unique hs
enhancer, the effects of dioxin on Igh transcription, and the impact that dioxin has
on Ig production. Furthermore, an extensive review of the literature failed to
provide any information on any studies that investigated the “quality” of
antibodies produced by dioxin challenged mammals. The majority of the research
correlated the reduction of antibody production to reduced immunologic
capability. Provided that the hs3b and hs4 activity can induce VH gene mutations
and given the importance of these regions for somatic hypermutation
(Laurencikiene, Tamosiunas et al. 2007), could activation of the hs4 with dioxin
impact the overall affinity and avidity of the resultant Ig. Although technically
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challenging, it would be of great interest to evaluate the quality of the resultant
antibodies to effectively bind an antigen after dioxin exposure.
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CHAPTER 8. APPENDIX

LIST OF ABBREVIATIONS
3’IghRR: 3’Ig heavy chain regulatory region
AhR: Aryl hydrocarbon receptor
APC: Antigen presenting cells
AP-1: Activator protein 1
ARNT: AhR nuclear translocator protein
BCR: B-cell receptor
CD40L: CD40 ligand
CH: Constant region
ChIP: Chromatin Immunoprecipitation Assay
CpG: Cytosine-phosphate-Guanine (CpG)-oligodeoxynucleotides
DRE: Dioxin responsive elements
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ELISA: Enzyme-Linked Immunosorbent Assay
Eµ: µ enhancer
HAH: Halogenated aromatic hydrocarbons
HSP: Heat shock protien
Ig: Immunoglobulin
Ip’d: Immunoprecipitated
IΚK: I kappa Kinase
IL-1R-MyD88: Toll/interleukin 1 receptor-Myeloid Differentiation primary
response gene 88
KO: Knockout
LPS: Lipopolysaccharide
NF-κB: Nuclear factor-kappaB
OCT: Octamer-binding transcription factor
P23: Heat shock protein 23
PVC: Polyvinyl chloride
R848: Resiquimod
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SP1: Specificity protein 1
TCDD: 2,3,7,8-tetrachlorodibenzo-p-dioxin
TLR: Toll-Like Receptors
TIRAP: Toll/IL-1R domain-containing adaptor protein
VH: Variable heavy chain promoter
XAP2: X-associated protein
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